May 24, 2022 / 12:30PM GMT
Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
Well, good morning, everyone, and welcome to day 2 of the UBS Global Healthcare Conference. I'm Colin Bristow, one of the biotech pharma analysts here at UBS. It is my pleasure to have with me today, Mike Mason, President of Lilly Diabetes.
If anyone has a question, there's QR codes scattered around. And if you -- you can then submit it electronically, and it will magically appear up here on the iPad.
Mike, we've talked a lot. I know you have a lot to talk about. So I'll hand it over to you for some opening remarks, and we'll dig into some questions.
Michael B. Mason - Eli Lilly and Company - Senior VP & President of Lilly Diabetes
All right. Sounds good. Thanks, Colin. Thanks, everyone, online and in person. I like the setting. I feel like I'm back in the '70s, but this is great. But I -- no, I appreciate the interest in Lilly Diabetes. It's a fantastic time for us. We have a full pipeline of leading products.
First, I'll touch on Jardiance. We have a
Eli Lilly and Co at UBS Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers